Latest news with #TTS
Yahoo
16 hours ago
- Business
- Yahoo
European Value Stocks Trading At Estimated Discounts
Amid renewed uncertainty about U.S. trade policy and escalating geopolitical tensions in the Middle East, European markets have experienced a downturn, with major stock indexes like Germany's DAX and Italy's FTSE MIB seeing significant declines. In this environment of market volatility, identifying value stocks—those trading at prices lower than their intrinsic worth—can present opportunities for investors seeking potential discounts in the European market. Name Current Price Fair Value (Est) Discount (Est) VIGO Photonics (WSE:VGO) PLN518.00 PLN1019.78 49.2% TTS (Transport Trade Services) (BVB:TTS) RON4.31 RON8.45 49% Sparebank 68° Nord (OB:SB68) NOK180.00 NOK358.42 49.8% Qt Group Oyj (HLSE:QTCOM) €54.60 €108.05 49.5% Lectra (ENXTPA:LSS) €23.90 €46.66 48.8% Koskisen Oyj (HLSE:KOSKI) €8.80 €17.34 49.2% Società Benefit (BIT:ICOP) €13.00 €25.66 49.3% doValue (BIT:DOV) €2.22 €4.43 49.9% CTT Systems (OM:CTT) SEK208.50 SEK407.80 48.9% Boreo Oyj (HLSE:BOREO) €14.85 €29.48 49.6% Click here to see the full list of 179 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's dive into some prime choices out of the screener. Overview: Lumibird SA designs, manufactures, and sells lasers for scientific, industrial, and medical applications internationally, with a market cap of €352.15 million. Operations: The company's revenue is primarily derived from its Medical segment, contributing €107.75 million, and its Photonic segment, which adds €99.37 million. Estimated Discount To Fair Value: 35% Lumibird is trading at €16, significantly below its estimated fair value of €24.62, presenting a compelling case for undervaluation based on discounted cash flow analysis. Despite high share price volatility and low forecasted return on equity of 8.7%, Lumibird's earnings are expected to grow significantly at 37.3% annually, outpacing the French market's average growth rate. Revenue growth is also projected to exceed the market average, enhancing its attractiveness despite recent large one-off items affecting results. The growth report we've compiled suggests that Lumibird's future prospects could be on the up. Click here to discover the nuances of Lumibird with our detailed financial health report. Overview: Kempower Oyj specializes in manufacturing and selling electric vehicle charging equipment and solutions for various modes of transportation across the Nordics, Europe, North America, and globally, with a market cap of €584.20 million. Operations: The company's revenue is primarily derived from its electric equipment segment, which generated €224.60 million. Estimated Discount To Fair Value: 20.6% Kempower Oyj, trading at €10.55, is undervalued compared to its estimated fair value of €13.29, based on discounted cash flow analysis. While the company is not yet profitable, it is expected to achieve profitability within three years with earnings forecasted to grow significantly by 59.84% annually. Recent strategic moves include a four-year testing collaboration with Etteplan and securing a €40 million green revolving credit facility, reinforcing its growth potential despite current share price volatility. According our earnings growth report, there's an indication that Kempower Oyj might be ready to expand. Get an in-depth perspective on Kempower Oyj's balance sheet by reading our health report here. Overview: Dätwyler Holding AG produces and sells elastomer components for various industries including healthcare, mobility, connectors, general, and food and beverage across Europe, North America, South America, Australia, and Asia with a market cap of CHF2.04 billion. Operations: The company's revenue is derived from two main segments: Healthcare Solutions, contributing CHF446 million, and Industrial Solutions, contributing CHF664.80 million. Estimated Discount To Fair Value: 41.2% Dätwyler Holding, trading at CHF120, is significantly undervalued compared to its estimated fair value of CHF204.01 based on discounted cash flow analysis. Although profit margins have decreased from last year and the dividend yield of 2.67% is not well-covered by earnings, the company's earnings are forecasted to grow substantially at 33.6% annually over the next three years, surpassing Swiss market growth expectations and indicating strong future profitability potential despite current financial challenges. The analysis detailed in our Dätwyler Holding growth report hints at robust future financial performance. Dive into the specifics of Dätwyler Holding here with our thorough financial health report. Reveal the 179 hidden gems among our Undervalued European Stocks Based On Cash Flows screener with a single click here. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTPA:LBIRD HLSE:KEMPOWR and SWX:DAE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Business Wire
2 days ago
- Health
- Business Wire
Newly Published Health Economics Study Demonstrates In-Office Ear Tube Procedures with Hummingbird TTS Significantly Reduce Healthcare Costs
GOLDEN VALLEY, Minn.--(BUSINESS WIRE)-- Preceptis Medical, Inc., a pioneer in pediatric ENT innovation, today announced the publication of a health economic study assessing the financial impact of shifting pediatric tympanostomy tube (ear tube) placement from operating room to in-office settings. The analysis, published in the Journal of Medical Economics, demonstrates significant cost savings potential for Commercial and Medicaid health insurance payers that provide access to in-office ear tube procedures utilizing the Hummingbird ® Tympanostomy Tube System (TTS). "This analysis demonstrates that payers can also realize meaningful cost savings, even when accounting for the additional resources required to treat children in-office." Dr. Gene Liu, Study Co-Author Key findings from the study include 1: Current costs of ear tube surgeries are estimated to be $3.5 billion annually for the US Healthcare System: Ear tube surgeries in a Hospital Outpatient Department (HOPD) on average cost over $5,700 for a commercial plan and $2,100 for a Medicaid plan Higher costs of OR-based surgeries are driven by the costs of the operating room, anesthesia, pre- and post-surgery care, and additional pre-operative testing Shifting ear tube procedures from the OR to the Office could save: Up to $3,743 per patient (65% cost savings) for a Commercial health plan Up to $519 per patient (24% cost savings) for a Medicaid health plan The procedural cost savings were significant even after accounting for the increased costs of pediatric in-office ear tube procedures, including the costs of the Hummingbird ® TTS Pediatric ear tube surgeries historically have been performed in the operating room (OR) under general anesthesia. However, the procedure can be safely and effectively performed in an office setting by using the Hummingbird ® TTS, helping pediatric patients avoid risks associated with operating room surgeries and general anesthesia exposure 2. This analysis demonstrates that in addition to the important clinical and safety benefits, Payers may also experience significant cost savings. 'Shifting ear tube placement into the office with the Hummingbird ® Device has improved patient access and offered families an important alternative to OR-based surgeries,' said Dr. Gene Liu, Pediatric Otolaryngologist at Cedars-Sinai Medical Center. 'This analysis demonstrates that payers can also realize meaningful cost savings, even when accounting for the additional resources required to treat children in-office. My hope is that these findings encourage payers to establish sustainable reimbursement rates that expand access to this safe and cost-effective option.' To support patient access to pediatric in-office ear tube procedures with tympanostomy tube delivery devices, the Centers for Medicare & Medicaid Services (CMS) established add-on HCPCS Code (+G0561) in the 2025 Physician Fee Schedule 3. CMS stated in the 2025 PFS, 'These minimally invasive, in-office procedures can offer significant benefits, including reduced risks associated with general anesthesia, quicker recovery, fewer infections, and improved access to care.' The new add-on G code facilitates fair reimbursement to providers for the incremental work and practice expenses (including device costs) involved in performing pediatric ear tube procedures in-office. This is the first economic study to evaluate the economic impact of utilizing the add-on code +G0561. 'This study reinforces what we have seen in our Health System, where we have been offering in-office ear tube procedures with the Hummingbird Device since 2021,' shared Dr. Mark Gerber, Pediatric Otolaryngologist at Phoenix Children's Hospital. 'Providing a mechanism for reimbursement for the incremental costs of the pediatric procedure will remove a significant barrier to utilization and save healthcare dollars.' About Preceptis Medical Founded in 2011, Preceptis Medical is an innovative medical technology company dedicated to providing less invasive ear tube procedure options for pediatric patients. The FDA-cleared Hummingbird ® Tympanostomy Tube System (TTS) streamlines ear tube placement, which enables the procedure to be performed with only a topical anesthetic. The Hummingbird, indicated for use in patients 6 months of age and older, provides a simple and efficient option for ENTs and parents while reducing healthcare costs. For more information, please visit Moynihan, M., Ross, R., Delgado, J., Gerber, M., & Liu, G. (2025). Economic impact of in-office pediatric tympanostomy tube placement using a tympanostomy tube delivery device in a commercially- and Medicaid-insured US population. Journal of Medical Economics, 28 (1), 899–909 Truitt MD, Theodore O., et al. 'In-office insertion tympanostomy tubes in children using single-pass device' Laryngoscope Investigative Otolaryngology. 2021;6:325-331.
Yahoo
4 days ago
- Business
- Yahoo
Discover 3 European Stocks Estimated To Trade Below Intrinsic Value By Up To 48.2%
The European stock markets have recently experienced a downturn, with the pan-European STOXX Europe 600 Index falling 1.57% amid renewed uncertainty surrounding U.S. trade policy and escalating geopolitical tensions in the Middle East. Despite these challenges, investors are on the lookout for opportunities, focusing on stocks that may be trading below their intrinsic value due to temporary market pressures or broader economic concerns. Name Current Price Fair Value (Est) Discount (Est) VIGO Photonics (WSE:VGO) PLN520.00 PLN1023.60 49.2% TTS (Transport Trade Services) (BVB:TTS) RON4.275 RON8.43 49.3% Sparebank 68° Nord (OB:SB68) NOK183.40 NOK365.75 49.9% Montana Aerospace (SWX:AERO) CHF20.00 CHF39.24 49% Lectra (ENXTPA:LSS) €23.60 €46.53 49.3% Exsitec Holding (OM:EXS) SEK132.00 SEK256.86 48.6% dormakaba Holding (SWX:DOKA) CHF717.00 CHF1400.68 48.8% BigBen Interactive (ENXTPA:BIG) €1.082 €2.11 48.6% Absolent Air Care Group (OM:ABSO) SEK212.00 SEK416.91 49.1% ABO Energy GmbH KGaA (XTRA:AB9) €35.70 €71.01 49.7% Click here to see the full list of 177 stocks from our Undervalued European Stocks Based On Cash Flows screener. Let's explore several standout options from the results in the screener. Overview: S.p.A. Società Benefit offers construction and special engineering services to both public and private clients in Italy and internationally, with a market cap of €345.43 million. Operations: The company's revenue is primarily derived from its heavy construction segment, totaling €110.92 million. Estimated Discount To Fair Value: 48.2% Società Benefit is trading significantly below its estimated fair value of €24.15, with a current price of €12.5, indicating it may be undervalued based on cash flows. The company reported a substantial increase in net income to €17.86 million for 2024 from the previous year, and earnings are forecast to grow at 28.78% annually, outpacing the Italian market's growth rate of 7.4%. However, its share price has been highly volatile recently. The analysis detailed in our Società Benefit growth report hints at robust future financial performance. Unlock comprehensive insights into our analysis of Società Benefit stock in this financial health report. Overview: Pexip Holding ASA is a video technology company that offers an end-to-end video conferencing platform and digital infrastructure across various regions including the Americas, Europe, the Middle East, Africa, and the Asia Pacific, with a market capitalization of NOK6.27 billion. Operations: The company's revenue primarily comes from the sale of collaboration services, amounting to NOK1.17 billion. Estimated Discount To Fair Value: 20.4% Pexip Holding is trading at NOK 61.6, significantly below its estimated fair value of NOK 77.42, suggesting it could be undervalued based on cash flows. The company's earnings are expected to grow at 23.7% annually, surpassing the Norwegian market's growth rate of 8.3%. Recent announcements include a share repurchase program and a partnership expansion with Google, enhancing interoperability for video meetings across platforms like Microsoft Teams and Zoom from Google Meet hardware. Upon reviewing our latest growth report, Pexip Holding's projected financial performance appears quite optimistic. Get an in-depth perspective on Pexip Holding's balance sheet by reading our health report here. Overview: SmartCraft ASA offers software solutions tailored for the construction industry across Norway, Sweden, Finland, and the United Kingdom, with a market cap of NOK4.41 billion. Operations: SmartCraft ASA generates revenue from providing software solutions to the construction sectors in Norway, Sweden, Finland, and the United Kingdom. Estimated Discount To Fair Value: 26.8% SmartCraft, trading at NOK 26.6, is priced below its estimated fair value of NOK 36.36, highlighting potential undervaluation based on cash flows. The company's earnings are forecast to grow significantly at 27.3% annually, outpacing the Norwegian market's growth rate of 8.3%. Recent product launches like SmartCraft Spark and Congrid's BIM feature aim to enhance efficiency in electrical and construction sectors, although profit margins have declined from last year's figures. Our comprehensive growth report raises the possibility that SmartCraft is poised for substantial financial growth. Delve into the full analysis health report here for a deeper understanding of SmartCraft. Get an in-depth perspective on all 177 Undervalued European Stocks Based On Cash Flows by using our screener here. Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include BIT:ICOP OB:PEXIP and OB:SMCRT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
5 days ago
- Business
- Yahoo
European Market Value Stock Picks For Estimated Intrinsic Value Opportunities
As European markets grapple with renewed uncertainty due to U.S. trade policy shifts and geopolitical tensions in the Middle East, the pan-European STOXX Europe 600 Index has seen a notable decline of 1.57%. In this climate, identifying stocks that are potentially undervalued can offer investors opportunities to align their portfolios with companies trading below their estimated intrinsic value, providing room for potential growth despite broader market challenges. Name Current Price Fair Value (Est) Discount (Est) VIGO Photonics (WSE:VGO) PLN518.00 PLN1023.50 49.4% TTS (Transport Trade Services) (BVB:TTS) RON4.265 RON8.43 49.4% Sparebank 68° Nord (OB:SB68) NOK183.40 NOK365.74 49.9% Qt Group Oyj (HLSE:QTCOM) €55.65 €107.98 48.5% Montana Aerospace (SWX:AERO) CHF19.58 CHF38.95 49.7% Lectra (ENXTPA:LSS) €23.65 €46.54 49.2% Exsitec Holding (OM:EXS) SEK132.00 SEK256.86 48.6% Etteplan Oyj (HLSE:ETTE) €10.60 €20.47 48.2% dormakaba Holding (SWX:DOKA) CHF716.00 CHF1400.46 48.9% BigBen Interactive (ENXTPA:BIG) €1.06 €2.11 49.7% Click here to see the full list of 174 stocks from our Undervalued European Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Montana Aerospace AG designs, develops, and manufactures system components and complex assemblies on a global scale, with a market cap of CHF1.21 billion. Operations: The company's revenue is primarily derived from its Aerostructures segment at €829.17 million and its Energy segment at €665.38 million. Estimated Discount To Fair Value: 49.7% Montana Aerospace AG's recent earnings report shows a strong performance with Q1 sales increasing to €410.86 million and net income rising to €5.27 million. The company is trading at CHF19.58, significantly below its estimated fair value of CHF38.95, indicating potential undervaluation based on cash flows. Despite high share price volatility and expected revenue growth of 5.8% per year, earnings are projected to grow significantly at 42.1% annually, outpacing the Swiss market average. Insights from our recent growth report point to a promising forecast for Montana Aerospace's business outlook. Click to explore a detailed breakdown of our findings in Montana Aerospace's balance sheet health report. Overview: FACC AG, with a market cap of €302.67 million, develops, produces, and maintains aircraft components globally through its subsidiaries. Operations: The company's revenue is primarily derived from three segments: Aerostructures (€353.71 million), Cabin Interiors (€389.49 million), and Engines & Nacelles (€170.03 million). Estimated Discount To Fair Value: 44.7% FACC, trading at €6.61, is significantly undervalued with a fair value estimate of €11.95 based on discounted cash flow analysis. Despite recent volatility and lower net profit margins compared to last year, the company's revenue grew to €230.96 million in Q1 2025 from €202.36 million a year ago. Earnings are forecasted to grow substantially at 70.9% annually over the next three years, outpacing the Austrian market's average growth rate. Our growth report here indicates FACC may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of FACC. Overview: Carl Zeiss Meditec AG is a medical technology company operating in Germany, the rest of Europe, North America, and Asia with a market cap of €5.35 billion. Operations: The company generates revenue from two main segments: Microsurgery, which accounts for €472.67 million, and Ophthalmic Devices (including Surgical Ophthalmology), contributing €1.70 billion. Estimated Discount To Fair Value: 40.5% Carl Zeiss Meditec, trading at €61.1, is undervalued with a fair value estimate of €102.62 based on discounted cash flow analysis. Despite a decline in profit margins from 12.7% to 7.2%, the company's earnings are expected to grow significantly at over 20% annually. Recent product approvals in China and strategic leadership changes could bolster future performance, as the company continues to innovate within its medical technology segment. Upon reviewing our latest growth report, Carl Zeiss Meditec's projected financial performance appears quite optimistic. Delve into the full analysis health report here for a deeper understanding of Carl Zeiss Meditec. Click through to start exploring the rest of the 171 Undervalued European Stocks Based On Cash Flows now. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SWX:AERO WBAG:FACC and XTRA:AFX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
5 days ago
- Business
- Yahoo
European Market Value Stock Picks For Estimated Intrinsic Value Opportunities
As European markets grapple with renewed uncertainty due to U.S. trade policy shifts and geopolitical tensions in the Middle East, the pan-European STOXX Europe 600 Index has seen a notable decline of 1.57%. In this climate, identifying stocks that are potentially undervalued can offer investors opportunities to align their portfolios with companies trading below their estimated intrinsic value, providing room for potential growth despite broader market challenges. Name Current Price Fair Value (Est) Discount (Est) VIGO Photonics (WSE:VGO) PLN518.00 PLN1023.50 49.4% TTS (Transport Trade Services) (BVB:TTS) RON4.265 RON8.43 49.4% Sparebank 68° Nord (OB:SB68) NOK183.40 NOK365.74 49.9% Qt Group Oyj (HLSE:QTCOM) €55.65 €107.98 48.5% Montana Aerospace (SWX:AERO) CHF19.58 CHF38.95 49.7% Lectra (ENXTPA:LSS) €23.65 €46.54 49.2% Exsitec Holding (OM:EXS) SEK132.00 SEK256.86 48.6% Etteplan Oyj (HLSE:ETTE) €10.60 €20.47 48.2% dormakaba Holding (SWX:DOKA) CHF716.00 CHF1400.46 48.9% BigBen Interactive (ENXTPA:BIG) €1.06 €2.11 49.7% Click here to see the full list of 174 stocks from our Undervalued European Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Montana Aerospace AG designs, develops, and manufactures system components and complex assemblies on a global scale, with a market cap of CHF1.21 billion. Operations: The company's revenue is primarily derived from its Aerostructures segment at €829.17 million and its Energy segment at €665.38 million. Estimated Discount To Fair Value: 49.7% Montana Aerospace AG's recent earnings report shows a strong performance with Q1 sales increasing to €410.86 million and net income rising to €5.27 million. The company is trading at CHF19.58, significantly below its estimated fair value of CHF38.95, indicating potential undervaluation based on cash flows. Despite high share price volatility and expected revenue growth of 5.8% per year, earnings are projected to grow significantly at 42.1% annually, outpacing the Swiss market average. Insights from our recent growth report point to a promising forecast for Montana Aerospace's business outlook. Click to explore a detailed breakdown of our findings in Montana Aerospace's balance sheet health report. Overview: FACC AG, with a market cap of €302.67 million, develops, produces, and maintains aircraft components globally through its subsidiaries. Operations: The company's revenue is primarily derived from three segments: Aerostructures (€353.71 million), Cabin Interiors (€389.49 million), and Engines & Nacelles (€170.03 million). Estimated Discount To Fair Value: 44.7% FACC, trading at €6.61, is significantly undervalued with a fair value estimate of €11.95 based on discounted cash flow analysis. Despite recent volatility and lower net profit margins compared to last year, the company's revenue grew to €230.96 million in Q1 2025 from €202.36 million a year ago. Earnings are forecasted to grow substantially at 70.9% annually over the next three years, outpacing the Austrian market's average growth rate. Our growth report here indicates FACC may be poised for an improving outlook. Click here and access our complete balance sheet health report to understand the dynamics of FACC. Overview: Carl Zeiss Meditec AG is a medical technology company operating in Germany, the rest of Europe, North America, and Asia with a market cap of €5.35 billion. Operations: The company generates revenue from two main segments: Microsurgery, which accounts for €472.67 million, and Ophthalmic Devices (including Surgical Ophthalmology), contributing €1.70 billion. Estimated Discount To Fair Value: 40.5% Carl Zeiss Meditec, trading at €61.1, is undervalued with a fair value estimate of €102.62 based on discounted cash flow analysis. Despite a decline in profit margins from 12.7% to 7.2%, the company's earnings are expected to grow significantly at over 20% annually. Recent product approvals in China and strategic leadership changes could bolster future performance, as the company continues to innovate within its medical technology segment. Upon reviewing our latest growth report, Carl Zeiss Meditec's projected financial performance appears quite optimistic. Delve into the full analysis health report here for a deeper understanding of Carl Zeiss Meditec. Click through to start exploring the rest of the 171 Undervalued European Stocks Based On Cash Flows now. Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SWX:AERO WBAG:FACC and XTRA:AFX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
